Association between the rs1007888 polymorphism of macrophage migration inhibitory factor gene and coronary heart disease in the Kazakhs of China

doi:10.3969/j.issn.2095-4344.2015.02.013

Abstract

Abstract:

BACKGROUND: Macrophage migration inhibitory factor (MIF) is a multi-potent cytokine that makes considerable contribution to the regulation of inflammatory response and immune response in the body. MIF rs1007888 is associated with various inflammatory diseases, but the correlation between rs1007888 and coronary heart disease in the Kazakhs of China has been rarely explored.
OBJECTIVE: To investigate the relationship between rs1007888 gene polymorphisms in MIF gene and coronary heart disease in the Kazakhs from Xinjiang Uygur Autonomous Region, China.
METHODS: A total of 230 Kazakh patients with coronary heart disease evidenced by coronary arteriography between December 2012 and July 2014 were recruited, and another 478 Kazak controls were free from coronary artery disease with normal angiograms. Real-time fluorescence quantitative PCR assay was used to detect the rs1007888 polymorphisms of MIF gene. Allele and genotype distributions of the rs1007888 polymorphism were
compared between patients and controls.
RESULTS AND CONCLUSION: Distribution of genotypes in the two groups appeared to be in Hardy-Weinberg equilibrium (P > 0.05). The allele frequencies and genotypes of MIF-rs1007888 showed no significant difference between the two groups (P > 0.05). Therefore, the genetic variation of rs1007888 in MIF gene is not associated with coronary heart disease in the Kazakhs of China.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: Polymorphism, Single Nucleotide, Genotype, Alleles, Gene Frequency

CLC Number:

R318

Xu Rui, Yang Yi-ning, Ma Yi-tong, Li Xiao-mei, Zhao Qian, Chen Bang-dang, Liu Fen . Association between the rs1007888 polymorphism of macrophage migration inhibitory factor gene and coronary heart disease in the Kazakhs of China[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(2): 231-235.

Figures/Tables 2

References

[1] Ko DT, Wijeysundera HC, Udell JA, et al. Traditional cardiovascular risk factors and the presence of obstructive coronary artery disease in men and women. Can J Cardiol. 2014;30(7):820-826.
[2] Legein B, Temmerman L, Biessen EA, et al. Inflammation and immune system interactions in atherosclerosis. Cell Mol Life Sci. 2013;70(20):3847-3869.
[3] Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 1966; 153(3731):80-82.
[4] Gong Z, Xing S, Zheng F, et al. Increased expression of macrophage migration inhibitory factor in aorta of patients with coronary atherosclerosis. J Cardiovasc Surg (Torino). 2014 [Epub ahead of print].
[5] White DA, Su Y, Kanellakis P, et al. Differential roles of cardiac and leukocyte derived macrophage migration inhibitory factor in inflammatory responses and cardiac remodelling post myocardial infarction. J Mol Cell Cardiol. 2014;69:32-42.
[6] Llamas-Covarrubias MA, Valle Y, Bucala R, et al. Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine. 2013;61(3):759-765.
[7] Adamali H, Armstrong ME, McLaughlin AM, et al. Macrophage migration inhibitory factor enzymatic activity, lung inflammation, and cystic fibrosis. Am J Respir Crit Care Med. 2012;186(2):162-169.
[8] Zhang H, Ma L, Dong LQ, et al. Association of the macrophage migration inhibitory factor gene--173G/C polymorphism with inflammatory bowel disease: a meta-analysis of 4296 subjects. Gene. 2013;526(2):228-231.
[9] De la Cruz-Mosso U, Bucala R, Palafox-Sanchez CA, et al. Macrophage migration inhibitory factor: association of -794 CATT5-8 and -173 G>C polymorphisms with TNF-alpha in systemic lupus erythematosus. Human Immunol. 2014;75(5): 433-439.
[10] Radstake, TR, Sweep FC, Welsing P, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum. 2005;52(10):3020-3029.
[11] Grieb G, Merk M, Bernhagen J, et al. Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect. 2010;23(4):257-264.
[12] Schober A, Bernhagen J, Thiele M, et al. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation. 2004;109(3):380-385.
[13] Coban N, Onat A, Yildirim O, et al. Oxidative stress-mediated (sex-specific) loss of protection against type-2 diabetes by macrophage migration inhibitory factor (MIF)-173G/C polymorphism. Clin Chim Acta. 2014;438C:1-6.
[14] Aslani S, Hossein-nezhad A, Maghbooli Z, et al. Genetic variation in macrophage migration inhibitory factor associated with gestational diabetes mellitus and metabolic syndrome. Horm Metab Res. 2011;43(8):557-561.
[15] Herder C, Klopp N, Baumert J, et al. Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984-2002. Diabetologia. 2008;51 (2):276-284.
[16] Herder C, Illig T, Baumert J, et al. Macrophage migration inhibitory factor (MIF) and risk for coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Atherosclerosis. 2008;200(2):380-388.
[17] 刘成,马翔,马依彤,等.新疆地区汉族、维吾尔族、哈萨克族成年人群超重和肥胖流行病学调查[J].中华流行病学杂志, 2010, 31(10):1139-1143.
[18] 李为民,刘巍.2005年中国高血压防治指南评价[J].中国实用内科杂志,2007,27(12):899-902.
[19] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2007年版) [J].中华医学杂志,2008,88(18):1227-1245.
[20] Herder C, Baumert J, Zierer A, et al. Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study. PLoS One. 2011;6(6):e19852.
[21] Cho Y, Baldan A. Quest for new biomarkers in atherosclerosis. Mo Med. 2013;110(4): 325-330.
[22] Pan JH, Sukhova GK, Yang JT, et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2004;109(25):3149-53.
[23] Schober A, Bernhagen J, Weber C. Chemokine-like functions of MIF in atherosclerosis. J Mol Med. 2008;86(7):761-770.
[24] Tereshchenko IP, Petrkova J, Mrazek F, et al. The macrophage migration inhibitory factor (MIF) gene polymorphism in Czech and Russian patients with myocardial infarction. Clin Chim Acta. 2009;402(1-2):199-202.
[25] O'Keefe JH Jr, Lavie CJ Jr., McCallister BD. Insights into the pathogenesis and prevention of coronary artery disease. Mayo Clin Proc. 1995;70(1):69-79
[26] Lv X, Zhang Y, Rao S, et al. Joint effects of genetic variants in multiple loci on the risk of coronary artery disease in Chinese Han subjects. Circ J. 2012;76(8):1987-1992.
[27] Adi D, Xie X, Ma YT, et al. Association of COL4A1 genetic polymorphisms with coronary artery disease in Uygur population in Xinjiang, China. Lipids Health Dis. 2013;12:153.
[28] Li X, Ma YT, Xie X, et al. Association of Egr3 genetic polymorphisms and coronary artery disease in the Uygur and Han of China. Lipids Health Dis. 2014;13:84.
[29] Villegas R, Goodloe RJ, McClellan BE Jr, et al. Gene-carbohydrate and gene-fiber interactions and type 2 diabetes in diverse populations from the National Health and Nutrition Examination Surveys (NHANES) as part of the Epidemiologic Architecture for Genes Linked to Environment (EAGLE) study. BMC Genet. 2014;15:69.
[30] Aguilar-Salinas CA, Tusie-Luna T, Pajukanta P. Genetic and environmental determinants of the susceptibility of Amerindian derived populations for having hypertriglyceridemia. Metabolism. 2014;63(7):887-894.